Fate Therapeutics (FATE) Piper Sandler 36th Annual Healthcare Conference summary

Leadership and organizational updates

• President and CEO Scott Wolchko announced retirement; Bob Valamehr to assume the role at the start of next year.

• Focus on advancing iPSC-based therapies for cancer and autoimmune diseases under new leadership.

Scientific and clinical highlights

• iPSC technology enables scalable, continuous production of effector cells for therapy.

• FT819, a CD19 CAR T cell therapy, uses precision engineering to eliminate TCR and insert CAR, reducing GVHD risk.

• First SLE patient treated with FT819 showed significant clinical improvement and B cell reset with a favorable safety profile using bendamustine conditioning.

• Upcoming data updates for additional FT819 patients expected at ASH, with dose expansion and escalation planned in SLE.

Pipeline and trial development

• FT522, a five-edited CAR NK cell, demonstrated safety and functional persistence in lymphoma without conditioning chemotherapy.

• IND cleared for a basket trial of FT522 in four autoimmune diseases: SSc, IIM, AAV, and SLE.

• Initial data from the FT522 autoimmune basket trial anticipated in the second half of next year.

• Dose expansion and escalation for FT819 will focus on SLE cohorts.